首席執行官Sung Kim在2025年醫療設備開發計劃簡報中代表Apex AI，推動我們對KFDA批准的戰略方法，以實現我們的AI驅動早期腸胃癌檢測。 下一步： • 在韓國第七大醫院的Ajou大學醫院和目前的合作夥伴Inha大學醫院（第十三名）進行對比評估，以優化KFDA批准路徑。 • 利用新的韓國AI醫療設備法規和ISO對接，加快未來美國FDA的申請。 前方有清晰的監管跑道。AI驅動的早期腸胃癌檢測比以往任何時候都更接近。

MAJOR UPDATE AT INHA UNIVERSITY HOSPITAL Apex AI's acute‑kidney‑injury predictor is now integrated with Inha University Hospital's next‑gen data center. Soon, live ICU vitals and lab results will stream straight into the Apex AI engine, which detects the earliest signs of kidney stress and alerts clinicians in time to act before irreversible damage sets in. The same platform that underpins our GI‑cancer detection system is architected to tackle various other critical conditions. Wherever real‑time clinical data lives, Apex AI can turn it into life‑saving foresight. Stay tuned for what’s coming next.

SaMD Approval Countdown Has Begun Apex AI CEO Sung  Kim locked in the roadmap with Ajou University Hospital’s Medical‑Device Support Center and their leading GI team to take our GI cancer early‑detection AI through Korea’s SaMD (Software as a Medical Device) gate. Regulatory files are in prep, validation plans are set, and every box we tick moves the platform closer to real‑time deployment in hospitals. $APEX saves lives.

專利正式註冊 我們的專利在上個月獲得批准，現在已正式註冊！這項突破性的內部工具自動檢測醫療 AI 訓練過程中的假陽性和假陰性，大幅縮短開發時間和成本。 您可以使用專利號碼：1020200003735 自行驗證。